Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Ipilimumab; Nivolumab
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Mar 2018 According to a Bavarian Nordic media release, data will begin to emerge in 2018.
- 16 Sep 2017 Planned number of patients changed from 65 to 29.
- 16 Mar 2017 Status changed from not yet recruiting to recruiting.